| Cytokine blockade in inflammatory bowel diseases. | |
| | |
MedLine Citation:
|
PMID: 22053885 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Inflammatory bowel diseases (IBDs) are chronic disabling diseases with significant morbidity. A deregulated immune response towards the intestinal microbiota is thought to play an important role in the pathogenesis of IBD, and thus biological therapies targeting key molecules such as cytokines have been designed. Several anti-TNF-α agents are currently being used to treat Crohn's disease and ulcerative colitis. Although these molecules dramatically improved the treatment of patients, side effects and the development of antidrug antibodies limits their application. There is thus an urgent need for alternative approaches to decrease inflammation and limit immunogenicity. Small neutralizing molecules, active immunization, gene silencing, selective transcription inhibitors and delivery of agents through the oral route are some of the currently developed strategies to meet these needs. In parallel, neutralizing antibodies targeting other pathways of the immune system have been developed and tested. Antibodies targeting IL-12/IL-23 pathways, and proinflammatory cytokines such as IFN-γ, IL-17A, IL-2 and IL-6 often showed an initial promising result, but for none of these agents efficacy has unequivocally been established. Administration of the regulatory cytokines IL-10 and IL-11 also failed to induce reproducible clinical effects. This article focuses on the anti-TNF therapies and the current challenges with monoclonal antibody therapies, discusses the innovative strategies targeting cytokine pathways to decrease inflammation in the bowel, and summarizes the recently developed agents neutralizing proinflammatory cytokines. |
| | |
Authors:
|
Clémentine Perrier; Paul Rutgeerts |
Related Documents
:
|
18946325 - Inclusion body myositis: new insights into pathogenesis. 9176145 - Induction of human endothelial cell apoptosis requires both heat shock and oxidative st... 16206165 - Purinergic receptor antagonists inhibit odorant-induced heat shock protein 25 induction... 16790465 - Redox regulatory mechanisms in cellular stress responses. 12671185 - Suppression of fas-mediated signaling pathway is involved in zinc inhibition of ethanol... 14635145 - Involvement of growth factors in thymic involution. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Immunotherapy Volume: 3 ISSN: 1750-7448 ISO Abbreviation: Immunotherapy Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101485158 Medline TA: Immunotherapy Country: England |
Other Details:
|
Languages: eng Pagination: 1341-52 Citation Subset: IM |
Affiliation:
|
Division of Gastroenterology, University Hospital, Catholic University Leuven, Leuven, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.
Next Document: Notch and inflammatory T-cell response: new developments and challenges.